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Polo-Like Kinase 1 Is a Potential Therapeutic Target in
Human Melanoma
Ahmad Jalili1,4, Anna Moser1,4, Mikhail Pashenkov1,4,5, Christine Wagner1, Gaurav Pathria1,
Viola Borgdorff1,2, Melanie Gschaider1, Georg Stingl1, Sridhar Ramaswamy3 and Stephan N. Wagner1,2
Exploration of the human melanoma cell-cycle pathway can lead to identification of new therapeutic targets.
By gene set enrichment analysis, we identified the cell-cycle pathway and its member polo-like kinase 1 (Plk-1)
to be significantly overexpressed in primary melanomas and in melanoma metastases. In vitro expression of
Plk-1 was peaked at the G2/M phase of the cell cycle. Plk-1 knockdown/inhibition led to induction of apoptosis,
which was caspase-3/8-dependent and p53-independent, and involved BID and Bcl-2 proteins. Comparative
genomic hybridization/single-nucleotide polymorphism arrays showed no genetic alteration in the Plk-1 locus.
Previous suggestions and significant enrichment of the mitogen-activated protein kinase (MAPK) signaling
pathway pointed to potential regulation of Plk-1 by MAPK signaling. Inhibition of this pathway resulted in
decreased Plk-1 expression as a consequence of G1 cell-cycle arrest rather than direct regulation of Plk-1.
Inhibition of MAPK and Plk-1 had an additive effect on reduced cell viability. This study shows that in human
melanoma, Plk-1 expression is dynamically regulated during the cell cycle, knockdown of Plk-1 leads to
apoptotic cell death, and that a combination of Plk-1 and MAPK inhibition has an additive effect on melanoma
cell viability. We conclude that combined inhibition of Plk-1 and MAPK could be a potentially attractive strategy
in melanoma therapy.
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INTRODUCTION
Skin cancers are the most common cancers worldwide (Lotze
et al., 2001). After basal cell and squamous cell carcinoma,
melanoma is the third most common skin cancer in the
general population and the most common in young adults
aged 25–29 years (Linos et al., 2009). At the localized
stage, melanoma can be cured by surgery. However, at the
metastatic stage, it becomes a devastating and incurable
disease leading to patient’s death within a few months to a
year (Lotze et al., 2001). Conventional therapies such as
chemotherapy and radiotherapy have shown little success in
the treatment of metastasizing melanoma (Garbe et al.,
2010). This necessitates the search for new therapeutic
targets to combat melanoma particularly at the advanced
stage.
Genetic analysis of melanoma has shown this tumor to be
a heterogeneous cancer harboring frequent mutations in
genes involved in intracellular signal transduction cascades
regulating fundamental processes, such as cell cycle, cell
proliferation, survival, and resistance to chemotherapy/radio-
therapy (Kwong et al., 2007). The most important signaling
pathway in melanoma is the mitogen-activated protein kinase
(MAPK) pathway, in which two of its members, namely NRAS
or BRAF, harbor activating mutations in up to 80% of human
melanomas in a mutually exclusive manner (Fecher et al.,
2008). It has also recently been shown both in preclinical and
in clinical studies that targeting members of the MAPK
signaling pathway could have a therapeutic potential for
melanoma (Haass et al., 2008; Flaherty and Smalley, 2009).
Polo-like kinase 1 (Plk-1) is a mitotic serine/threonine
kinase. In humans, four structurally related Plks have been
identified (Plk-1, -2, -3, and -4), of which Plk-1 appears to be
indispensable for cell-cycle progression and presumably for
cancer cell proliferation (Barr et al., 2004). The kinase
activity of Plks is regulated at least in part, by the polo-boxes
that are functionally important for both auto-inhibition and
subcellular localization (Cheng et al., 2003). Levels and
activity of Plk-1 are low during the G1 and S phases of the
cell cycle, increase during the G2 phase, peak during the
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M phase, and rapidly decline as the cell exits mitosis
(Golsteyn et al., 1995; Whitfield et al., 2002).
Plk-1 is mostly expressed in rapidly proliferating tissues,
particularly in those with an unstable genome, such as cancer
cells (Guan et al., 2005). There is a substantial body of data
linking Plk-1 to cancer. Plk-1 is highly expressed in many
human tumors, such as breast, cervical, ovarian, thyroid,
gastric, hepatocellular, pancreatic, colorectal, prostate can-
cer, and melanoma, as well as non-melanoma skin cancers
(Takahashi et al., 2003; Gray et al., 2004; Weichert et al.,
2004; Schmit et al., 2009a, b). Interestingly, in some cancers
including melanoma, the expression of Plk-1 could be clearly
correlated with poor prognosis (Strebhardt et al., 2000;
Weichert et al., 2004, 2005; He et al., 2009). Constitutive
overexpression of Plk-1 induces rapid cell cycling and
confers an oncogenic transformed phenotype to NIH-3T3
fibroblasts (Smith et al., 1997).
Importantly, depletion of Plk-1 in normal (non-cancer) cell
lines does not arrest the cell cycle at least for the first few
divisions (Guan et al., 2005; Schmit et al., 2009b). Therefore,
therapeutic approaches targeting Plk-1 may predominantly
affect cancer cells, while sparing normal cells making
it an attractive target in the treatment of cancer. Indeed,
in vitro and in vivo preclinical studies have shown poten-
tial suitability of targeting Plk-1 in the treatment of
different cancers (Degenhardt and Lampkin, 2010; Wa¨sch
et al., 2010).
In this study, using cDNA microarray technique and gene
set enrichment analysis (GSEA) (Xu et al., 2008), we
identified the cell-cycle pathway to be enriched and its
member Plk-1 to be strongly upregulated in human primary
melanomas and in melanoma metastases as compared with
melanocytic nevi. Comparative genomic hybridization and
single-nucleotide polymorphism arrays showed no amplifica-
tions or deletions at the respective gene locus, therefore
ruling out a genetic alteration. We demonstrate that in the
absence of Plk-1, human melanoma cell lines including those
from the NCI-60 panel undergo p53-independent apoptotic
cell death. Furthermore, we show that the reduced levels of
Plk-1 subsequent to MAPK signaling blockade are merely a
consequence of G1 cell-cycle arrest rather than being a direct
regulation by the MAPK signaling pathway. In addition,
finally, a combination of MAPK inhibition and Plk-1 knock-
down has an additive effect in suppressing the viability of
human melanoma cell lines.
RESULTS
GSEA identifies the cell-cycle pathway and its member Plk-1
to be enriched and differentially expressed in primary
melanomas and in melanoma metastases as compared with
melanocytic nevi
We performed gene expression profiling on healthy skin,
melanocytic nevi, primary melanomas, melanoma meta-
stases, and human melanoma cell lines using Affymetrix
U133A Oligonucleotide Microarray platform (Affymetrix,
Santa Clara, CA). Using this strategy, we determined the
expression of 22,283 genes. GSEA (http://www.broadinstitute.
org/gsea) is a computational method that determines whether an
a priori defined set of genes shows statistically significant,
concordant differences between two biological states (Xu et al.,
2008). We obtained a list of genes most differentially expressed
between primary melanomas, melanoma metastases, and
melanocytic nevi (Supplementary Table 1 online). In addition,
by using GSEA and pathways from Biocarta (www.biocarta.
com), GenMAPP (www.genmapp.org), and KEGG (www.
genome.jp/kegg) databases, we could identify signaling
pathways that were enriched in primary melanomas and in
melanoma metastases as compared with melanocytic nevi
(Supplementary Table S2 online). Association of any of the 50
genes most overexpressed in primary melanomas and in
melanoma metastases with the corresponding enriched path-
ways in these groups would indicate the importance of a gene.
We observed the cell-cycle pathway to be the third most
significantly enriched pathway in primary melanomas and in
melanoma metastases as compared with melanocytic nevi
(P¼0.0008) after the MAPK pathway (P¼0.0003) and the
cyclin E destruction (fbw7) pathway (P¼0.0001).
Searching the 50 most overexpressed genes of primary
melanomas and metastases as compared with melanocytic
nevi for members of the cell-cycle pathway resulted in
identification of Plk-1 (the 37th most differentially expressed
gene). Interestingly, other members of the Plk family, Plk-2,
-3, and -4, were not present in this list and also showed no
significant expression difference between melanocytic nevi
and melanomas (data not shown).
The expression of Plk-1 is significantly higher in primary
melanomas and melanoma metastases than in melanocytic nevi
The gene microarray data showed relatively low expression
of Plk-1 melanocytic nevi. The expression was increased in
primary melanomas and was highest in melanoma metastases
(Figure 1a, Po0.001, analysis of variance with Tukey’s
post-test). Using an independent set of samples and
quantitative real-time PCR, a similar pattern of expression
was observed (Figure 1b, Po0.001, analysis of variance with
Tukey’s post-test).
The expression of Plk-1 is dynamically regulated in human
melanoma cell lines, and its peak expression is restricted to
the G2/M phase of the human melanoma cell cycle.
We used three well-established human melanoma cell
lines, M14 (NCI-60 panel of human cancer cell lines, http://
dtp.nci.nih.gov/docs/misc/common_files/cell_list.html), WM-115,
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Figure 1. Polo-like kinase 1 is highly expressed in human melanoma
metastases. (a) Gene expression profiling of melanocytic nevi (n¼9), primary
human melanoma (n¼ 31), and melanoma metastases (n¼52). Relative Plk-1
RNA expression is shown. (b) Quantitative real-time PCR technique
demonstrating relative Plk-1 RNA expression. **Po0.001, ANOVA test with
Tukey’s post-test. ANOVA, analysis of variance; Plk-1, polo-like kinase 1.
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and HT-144. Quantitative real-time RT-PCR analysis of
synchronized cells demonstrated expression of Plk-1 mRNA
to peak around 9–15 hours (cell line dependent and related to
the duration of the cell cycle) after release from a single
thymidine block (Figure 2a). Interestingly, double staining of
cells for Plk-1 and propidium iodide (PI) showed Plk-1-
positive cells to be tetraploid corresponding to cells present
in the G2/M phase of the cell cycle (Figure 2b). Phosphoryla-
tion at Ser10, Ser28, and Thr11 of histone H3 is tightly
correlated with chromosome condensation during mitosis
(Goto et al., 1999). Human melanoma cells expressing
phospho-histone H3 were all Plk-1 positive (Figure 2c),
further confirming our observation that Plk-1 expression is
mainly in the G2/M phase of the cell cycle.
Specific Plk-1 inhibition and Plk-1 knockdown in human
melanoma cell lines lead to decreased cell viability and
induction of apoptosis
To study the role of Plk-1 in human melanoma cell biology,
small-interfering RNA (siRNA)-based silencing was used.
Specific targeting of Plk-1 with commercially available Plk-1
siRNA and by transient transfection with pSuper vector
expressing self-designed Plk-1 siRNA led to significant
reduction in the Plk-1 mRNA (data not shown) and protein
in comparison with control siRNA-treated cells as shown by
western blot (WB) analysis (Figure 2d). We observed
significant reduction in the viability of M14 and WM-115
human melanoma cell lines as Plk-1 was silenced (Figure 2e).
This phenomenon was observed in 11 other human
melanoma cell lines including those from the NCI-60 panel
all expressing the Plk-1 protein (SK-MEL-2, SK-MEL-5, SK-
MEL-28, WM-35, LOX-IMVI, A375, HT-144, WM-983 A,
MEWO, UACC-62, and UACC-257, Supplementary Figure 1
online). Interestingly, specific inhibition of Plk-1 using the
commercially available inhibitor BI 2536 led to a dose- and
time-dependent decrease in human melanoma cell viability
(Figure 2f). There was a pronounced and significant
fragmentation of nuclei upon knockdown of Plk-1, a
phenomenon described to be associated with apoptosis or
mitotic catastrophe (Eom et al., 2005) (Figure 3a and b).
Decreased cell viability was accompanied by an increase in
apoptosis as shown by annexin V assay (Figure 3c). Indeed,
we also observed cleavage of caspase-3 and -8 upon Plk-1
knockdown as shown by WB analysis in Figure 3d. Cleaved
caspase-3 is a hallmark of apoptosis, and caspase-8 cleavage
points to the activation of the extrinsic pathway of apoptosis.
Interestingly, concomitant use of Plk-1 siRNA and pan-
caspase inhibitor (Apo-Block) led to complete rescue of cells
from apoptosis (Figure 3c). As caspase-8 cleavage was seen
upon Plk-1 silencing, it was important to see whether
caspase-8 inhibition could also cause a complete rescue
from apoptosis. To test this possibility, cells were concomi-
tantly treated with Plk-1 siRNA and a specific caspase-8
inhibitor (Z-IETD-FMK). The rescue was partial, suggesting
the involvement of both extrinsic and intrinsic branches of
apoptosis (Figure 3c).
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Figure 2. The expression of Plk-1 is dynamically regulated during human melanoma cell cycle and is vital for cell survival. (a) Human melanoma cell lines
WM-115, M14, and HT-144 were synchronized with thymidine (thymidine block) for 24 hours. Cells were collected at specific time points after thymidine
release; RNA was isolated and subjected to quantitative real-time PCR analysis for Plk-1 as shown by relative RNA expression. (b) Double staining with
propidium iodide (Y axis) and Plk-1 FITC or isotype control antibody (X axis) demonstrating double-positive cells to be tetraploid and restricted to the G2/M
phase of the cell cycle in WM-115 melanoma cell line. (c) All phospho-histone H3-positive WM-115 melanoma cells were co-expressing Plk-1 as shown
by flow cytometry. (d) WB analysis of Plk-1 protein 48 hours after siRNA-based gene silencing. Control siRNA represents negative control. (e and f) Plk-1
knockdown and inhibition by BI 2536 and viability of human melanoma cell lines M14 and WM-115 as demonstrated by MTT assay. Experiments were
performed in triplicate. One representative experiment is shown. *Po0.001, ANOVA test with Tukey’s post-test. ANOVA, analysis of variance; MTT,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Plk-1, polo-like kinase 1; siRNA, small-interfering RNA; WB, western blot.
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Induction of apoptosis by Plk-1 knockdown is p53 independent
The p53 pathway has previously been shown to be involved
in Plk-1 depletion-induced apoptosis (Liu and Erikson, 2003).
To see whether p53 is involved in the induction of apoptosis
after depletion of Plk-1 in human melanoma, melanoma cell
lines M14 (harboring heterozygous p53-inactivating mutation
(Ikediobi et al., 2006)) and WM-115 (p53 wild type) were
transfected with either Plk-1 or control-scrambled siRNAs,
and protein was extracted at different time points and
subjected to WB analysis for p53 protein. There was no
change in the expression of the p53 protein or its downstream
target p21 after Plk-1 knockdown as compared with the
control group at 12, 24, and 48 hours post-siRNA treatment
(Figure 4a). To further rule out the involvement of p53 in
Plk-1 knockdown-mediated apoptosis, p53 and Plk-1 were
simultaneously silenced. Despite a significant reduction in
the amount of p53 protein, cells could not be rescued
from the Plk-1 knockdown-mediated induction of apop-
tosis (Figure 4b). When screening for the involvement
of other potential candidates, we identified a decrease in
uncleaved BID and Bcl-2 (known as the inhibitor of
apoptosis) at 48 hours after Plk-1 silencing (Figure 4c) when
caspase-3 and -8 cleavage was also observed (Figure 3d).
There was no change in the protein levels of apoptosis-
inducing factor, Apaf-1, and caspase-9 belonging to the
intrinsic pathway of apoptosis (data not shown). Mitochon-
drial cytochrome c release was observed at a later time point
(72 hours after Plk-1 siRNA transfection, Supplementary
Figure 2 online). These results argue for the induction of both
intrinsic and extrinsic pathways of apoptosis after Plk-1
knockdown in melanoma cell lines.
MAPK inhibition induces cell-cycle arrest at the G1 phase and
decreased Plk-1 protein levels
MAPK is the most important signaling pathway in human
melanoma because of frequent mutations leading to
constitutive activation of the pathway (Fecher et al., 2008).
In GSEA, this pathway was also significantly enriched in
human primary melanomas and in melanoma metastases
than in melanocytic nevi (P¼ 0.0003). It has recently also
been suggested that the MAPK signaling pathway might
be regulating the expression of Plk-1 in chronic myeloid
leukemia (Gleixner et al., 2010). To see whether inhibition of
this pathway has an impact on the expression of Plk-1 in
human melanoma, we used specific inhibitors of mitogen-
activated protein kinase kinase (MEK) 1/2 (PD98059), c-Jun
N-terminal kinase (JNK) (JNK inhibitor II), p38 MAPK
(SB203580), and the multikinase inhibitor (sorafenib).
Treatment of human melanoma cell lines WM-115 and
M14 with these inhibitors was accompanied with signifi-
cant reduction of Plk-1 protein levels (Figure 5a). This
phenomenon was accompanied by induction of apoptosis
(Figure 5b). The MEK 1/2 inhibitor PD98059 inhibited
Plk-1 expression in a dose- and time-dependent manner
(data not shown).
It is known that MAPK inhibition results in cell-cycle arrest
at the G1 phase of the cell cycle (Koo et al., 2002). Therefore,
decreased expression of Plk-1 could be a consequence of
cell-cycle arrest rather than being a direct regulation by the
MAPK signaling pathways. Indeed, treatment of M14 and
WM-115 human melanoma cells with PD98059 led to cell-
cycle arrest at the G1 phase (Figure 6a). Continuous treat-
ment with PD98059 significantly reduced the Plk-1 protein
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Figure 3. Silencing of Plk-1 induces nuclear fragmentation and apoptosis. (a) PI staining of nucleic acids in WM-115 human melanoma cell line after
Plk-1 knockdown showing nuclear fragmentation,  200 magnification. Bar¼ 10mm. (b) Cells containing fragmented nuclei were counted in five different
visual fields and are presented as % apoptotic cells. (c and d) Annexin V/PI staining of M14 and WM-115 human melanoma cell lines after Plk-1 silencing
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level (Figure 6b), and discontinuation of this treatment led to
re-expression of the Plk-1 protein (Figure 6b).
As in PD98059-treated cells, thymidine block also led to a
cell-cycle arrest at the G1 phase (Figure 2a). Importantly, the
expression of the MAPK target protein-phospho-extracellular
signal-regulated kinase was not changed in human melano-
ma cell lines WM-115 and M14 after thymidine block, in
contrast to treatment with PD98059 that substantially
decreased its expression (Figure 6c). Both thymidine block
and PD98059 treatment resulted in decreased expression of
the Plk-1 protein (Figure 6c). These results further argue that
decreased expression of Plk-1 after MAPK inhibition is a
consequence of cell-cycle arrest rather than being a direct
regulation by the MAPK signaling pathway.
Simultaneous inhibition of MAPK and Plk-1 shows an additive
effect on reduced viability
As demonstrated above, inhibition of the MAPK signaling
pathway induces G1 phase cell-cycle arrest; however, Plk-1
knockdown results in a cell-cycle arrest at the G2 phase. Tar-
geting cells at both the G1 and G2 phase of the cell cycle should
theoretically result in a potentiation of either single treatment.
To explore this possibility, human melanoma cells were
treated with PD98059, Plk-1-specific siRNA/BI 2536, or a
combination of both and cell viability was determined
by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assay. Interestingly, combination of these
treatments in comparison with single treatments showed an
enhanced suppressive effect on cell viability, which was
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statistically significant (Figure 6d and Supplementary Figure 4
online).
DISCUSSION
Gene expression profiling is the measurement of the
expression of thousands of genes at once to create a global
picture of cellular function. This technique has shown to be
of potential use for the identification of target genes in cancer
for diagnostic, prognostic, and therapeutic purposes (Kwong
et al., 2007; Hartman et al., 2010; Subramanian and Simon,
2010).
In this study, we measured the expression of 422,000
genes in human primary and metastatic melanomas, as
well as in human melanocytic nevi. By GSEA, we were able
to obtain a list of the 50 most overexpressed genes in primary
melanomas and in melanoma metastases as compared with
melanocytic nevi. By integrating the results obtained from
GSEA with pathway enrichment analysis, we could identify
Plk-1 to be the only member of the enriched cell-cycle
pathway present in the list of the 50 most overexpressed
genes. Analysis of gene expression values of Plk-1 in melano-
cytic nevi, primary melanomas, and melanoma metastases
demonstrated a significant difference with an increasing trend
toward human melanoma metastases. This could be con-
firmed by using an independent set of samples and
quantitative real-time PCR for Plk-1 mRNA.
As expected, the higher Plk-1 expression in our gene
microarray data correlated with poorer prognosis (although
not significant, data not shown). It has also been previously
shown that primary melanomas with developed metastases
express Plk-1 at markedly elevated levels compared with
melanomas without metastases, suggesting Plk-1 expression
to be a reliable marker to identify patients at high risk for
metastases (Kneisel et al., 2002).
Using comparative genomic hybridization analysis and
single-nucleotide polymorphism arrays (data not shown) in
our samples, we found no genetic alterations at the gene
locus 16p12.1 where Plk-1 resides. There have also been no
reports in the literature about possible genetic alterations
affecting Plk-1 expression at this locus. Therefore,
we postulate that the reason behind the increased expression
of Plk-1 in primary melanomas and in melanoma metastases
is the increased proliferation rate of melanoma cells
as compared with cells in nevi, leading to increased Plk-1
expression rather than direct genetic alterations in the
Plk-1 locus.
Consistently, the expression of Plk-1 was dynamically
regulated during the human melanoma cell cycle as in earlier
reports. The peak expression value was observed during the
G2/M phase of the cell cycle. This has also been shown to be
the case in other cancer cells (Archambault and Glover,
2009). Specific knockdown of Plk-1 using commercially
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Figure 6. Downregulation of Plk-1 upon MAPK inhibition is a consequence of G1 cell-cycle arrest in human melanoma cell lines. (a) Cell-cycle
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48 hours). (b) M14 and WM-115 melanoma cell lines were treated with PD98059 (10 mM) for 24 hours. Cells were then washed and re-treated either
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available Plk-1 siRNA in human melanoma cell lines M14,
HT-144, and WM-115 led to cell-cycle arrest at the G2/M
phase of the cell cycle and decreased viability. This was
followed by nuclear fragmentation and caspase-3 and -8
cleavage. Interestingly, specific caspase-8 or pan-caspase
inhibition by small-molecule inhibitors or specific caspase-3
or/and -8 siRNA-based silencing (data not shown) was able to
partially to completely rescue cells from programmed cell
death or apoptosis.
In 14 human melanoma cell lines tested, including those
from the NCI-60 panel, all were sensitive to Plk-1 knock-
down. The degree of sensitivity did not correlate with the
origin of cells (primaries or metastatic melanoma, radial or
vertical growth phase) or mutational status (including BRAF,
NRAS, p53, PTEN, CDK4, CDKN2A, NF1, and ATM). It has
been previously shown that normal human epidermal
melanocytes are resistant to Plk-1 knockdown or inhibition
(Schmit et al., 2009b). Interestingly, in our hands, hTERT/
CDK4(R24C)/p53DD-immortalized human melanocytes were
more resistant to Plk-1 inhibition by BI 2536 as compared
with BRAFV600E-transformed cells (hTERT/CDK4(R24C)/p53DD/
BRAFV600E representing more the human melanoma cell lines
and needing a five times greater concentration of the inhibitor
to be growth arrested (Supplementary Figure 3 online).
It has been previously shown in other cancer cell lines that
lack of Plk-1 induces p53-dependent apoptosis (Liu and
Erikson, 2003). In our study, we observed no change in the
expression of p53 in the absence of Plk-1. In contrast, in both
human melanoma cell lines M14 (harboring a heterozygous
p53-inactivating mutation) and WM-115 (wild-type p53), the
expression of the anti-apoptotic protein Bcl-2 was substan-
tially decreased. Concomitant knockdown of p53 with
Plk-1 could not rescue the cells from Plk-1-mediated
induction of apoptosis arguing against an involvement of
the p53 pathway.
In the absence of Plk-1, cells underwent apoptosis with
caspase-3 and -8 cleavage. Interestingly, specific caspase-8 or
pan-caspase inhibition partially to completely rescued the cells.
Cleavage of caspase-3 and -8 together with a decrease in the
Bcl-2 protein level and cytochrome c release argues for the
induction of both extrinsic and intrinsic pathways of apoptosis.
Not surprisingly, the MAPK signaling pathway was the
second-most enriched pathway in primary melanomas and in
melanoma metastases (as compared with melanocytic nevi)
in our samples. It has recently also been suggested that the
MAPK signaling pathway might regulate expression of Plk-1
expression in some cancer cell lines, such as chronic myeloid
leukemia (Gleixner et al., 2010). Interestingly, inhibition of
MAP kinases MEK, JNK, p38, and multikinases (BRAF, CRAF,
VEGFP by sorafenib) in WM-115 and M14 human melanoma
cell lines led to either significant reduction or complete
inhibition of the Plk-1 protein expression. Inhibitors of MAPK
are also known to induce a cell-cycle arrest at the G1/S phase
(Pumiglia and Decker, 1997; Lee et al., 2002). Indeed, the
MEK 1/2 inhibitor PD98059 induced a G1/S arrest in both
human melanoma cell lines tested. The fact that thymidine
block of cells at the G1 phase, where the MAPK signaling
pathway is known not to be affected, had a similar effect on
Plk-1 expression (Figure 2a). This inhibition of Plk-1 expres-
sion by MAPK inhibitors might be rather the consequence of
a G1/S phase cell-cycle arrest than direct regulation of Plk-1
expression. Indeed, downregulation of Plk-1 expression and
G1 phase cell-cycle arrest upon thymidine block happens in
the presence of active MAPK signaling pathway as demon-
strated by the expression of phospho-p44/42 extracellular
signal-regulated kinase 1/2. Continuous treatment of human
melanoma cell lines WM-115 and M14 with MEK 1/2
inhibitor resulted in a significant decrease in Plk-1 protein
levels; however, removal of MEK 1/2 inhibition resulted in a
time-dependent re-expression of the Plk-1 protein.
Inhibitors of the MAP signaling pathway have recently
been shown to have therapeutic effects in various cancers,
including melanoma (Bollag et al., 2010; Flaherty et al.,
2010a, b; Smalley, 2010). These responses seem to be rapid
but short lasting; therefore, combination strategies targeting
members of other pathways such as cell cycle might open
new therapeutic possibilities. Interestingly, combination of
MAPK inhibition (G1 arrest) and Plk-1 knockdown (G2 arrest)
had a significant additive effect on decreased viability of
human melanoma cell lines.
Several small-molecule inhibitors of Plk-1 are currently in
pre-clinical and early clinical trials for the treatment of
various malignancies (Chopra et al., 2010; Degenhardt and
Lampkin, 2010; Hofheinz et al., 2010). On the basis of our
data, it would be worth trying these inhibitors in melanoma
patients keeping in mind that these inhibitors are shown not
to have any effect on normal melanocytes and also to spare
other normal non-cancerous cells (Schmit et al., 2009b).
Finally, we conclude that combination of MAPK and Plk-1
inhibition could be a potentially attractive therapeutic
strategy in melanoma.
MATERIALS AND METHODS
Cell lines, tissues, and reagents
Human melanoma cell lines WM-115 and HT-144 were obtained
from American Type Culture Collection (Manassas, VA). The M14
cell line was from DCTD Tumor Repository (National Cancer
Institute, Frederick, MD). Cells were cultured in RPMI 1640,
supplemented with 10% heat-inactivated fetal calf serum, and
2 mM L-glutamine (all from Invitrogen, Carlsbad, CA) and hereafter
referred to as culture medium. After seeding from cryopreserved
stock, cells were passaged at least 2–3 times before experiments.
Propidium iodide (Sigma-Aldrich, Vienna, Austria), thymidine
(Sigma-Aldrich), MEK 1 inhibitor PD98059, JNK inhibitor II, p38
inhibitor SB203580 (all from Merck KGaA, Darmstadt, Germany), as
well as BI 2536 and multikinase inhibitor sorafenib (both from
Selleck Chemicals LLC, Houston, TX) were used in this study.
RNA isolation, gene expression profiling, and quantitative
real-time PCR analysis
Total RNA was isolated from monolayer cell cultures and
cryopreserved tissues using TriReagent (Sigma, St Louis, MO)
according to the manufacturer’s instructions.
Tissue sampling and gene expression profiling were performed
using Affymetrix U133A microarray platform as described previously
(Xu et al., 2008). Tissue samples contained normal skin (n¼ 8),
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melanocytic nevi (n¼ 9), human primary melanoma (n¼ 31), and
melanoma metastases (n¼ 52). Institutional approval or patient
consent was not necessary. Microarray experiments were conducted
according to standard protocols for Affymetrix Genome U133A
arrays. In brief, 1 ı`g of total RNA was used to synthesize cDNA and
biotinylated cRNA using the GeneChip expression 3-amplification
reagent kits from Affymetrix. cRNA hybridization and scanning of
the array were performed according to the manufacturer’s protocols.
Gene set and pathway enrichment analyses have been performed
as described previously (Xu et al., 2008). The data have been
deposited in the National Center for Biotechnology Information GEO
(Clark et al., 2000) and are accessible through GEO Series accession
no. GSE8401.
For RT-PCR study, independent sets of 6 melanocytic nevi, 12
primary melanomas, and 12 metastatic melanoma tissues were used.
Reverse transcription was performed by SuperScript II reverse transcrip-
tase using random hexamer and oligo-dT primers (all from Invitrogen).
Plk-1, b-actin cDNAs, or 18S rRNA were amplified using primer/probe
sets no. Hs00153444, no. Hs99999903-m1, and no. Hs99999901-s1,
respectively, from Applied Biosystems (Foster City, CA). Reactions were
performed in an AbiPrism 7700 DNA amplifier under the following
conditions: initial heating at 501C for 2minutes and 951C for 10minutes,
followed by 40 cycles consisting of a denaturation step (901C,
15seconds) and an annealing/elongation step (601C, 1minutes). Each
sample was assayed in duplicate. Negative controls represented full PCR
reaction mixtures with cDNA substituted by ddH2O. The readout for
each reaction was cycle of threshold (Ct), i.e., the cycle number in which
the fluorescent signal became higher than a pre-defined threshold.
Levels of Plk-1 mRNA in tumor tissues were expressed
quantitatively as copy number of Plk-1 mRNA per 1,000 copies of
b-actin mRNA. Quantitation was performed using calibration curves
created using reference plasmids, which represented Plk-1 or b-actin
cDNA (GeneBank accession numbers NM_005030 and
NM_001101, respectively) cloned into the commercial pGEM-T
Easy plasmid (Stratagene, La Jolla, CA).
In all other experiments, levels of Plk-1 mRNA were expressed
semi-quantitatively using the DDCt method and 18S rRNA as a
reference gene, according to the formula:
2DDCt ¼ 2ððCt Plk1 sampleCt 18S sampleÞðCt Plk1 reference sampleCt 18S reference sampleÞÞ
Plk-1 detection in combination with cell-cycle analysis
For intracellular Plk-1 staining, melanoma cells were trypsinized,
washed, fixed with 70% ethanol (1hour on ice), permeabilized with
0.05% Tween (VWR International, Vienna, Austria) in phosphate-
buffered saline (PBS) (Invitrogen), and incubated for 30 minutes at room
temperature with either mouse anti-human Plk-1 mAb (ab 17057,
Abcam plc, Cambridge, UK) or a control IgG1 (Immunotech, Marseille,
France), both at 2.5mg ml. Subsequently, cells were washed and
incubated with FITC-labeled goat anti-mouse IgG F(ab0)2 fragments
(Immunotech) at a 1:300 dilution, whereafter again washed.
To simultaneously perform the analysis of Plk-1 expression and
cell-cycle analysis, cells were additionally incubated in a DNA
staining buffer (10 mg ml PI and 250mg ml RNAse A in PBS;
10 minutes at 371C). Cells were analyzed using a FACScan flow
cytometer and CellQuest software (both from BD Biosciences,
Vienna, Austria). Cells with different DNA content were gated
separately according to PI staining, and Plk-1 signal (expressed
as mean fluorescence intensity) was analyzed in the gated
sub-populations after subtraction of background mean fluorescence
intensity obtained from isotype control staining.
In some experiments, cells were stained with the mAb against
Plk-1 and a polyclonal rabbit antibody against human phospho-
histone H3 [pS10] (Invitrogen) to identify mitotic cells. The two
antibodies were visualized, respectively, by a phycoerythrine-
labeled anti-mouse Ab (Jackson Immunoresearch, West Grove, PA)
and an Alexa Fluor 488-labeled goat anti-rabbit Ab (Invitrogen).
siRNA transfection, cell-cycle analysis, and MTT assay
Transfection with validated Plk-1 (s448, Ambion, Austin, TX), p53
(sc-44218, Santa Cruz Biotechnology, Santa Cruz, CA), and negative
control (AM4637, Ambion) siRNAs was performed using Lipofecta-
mine 2000 transfection reagent (Invitrogen) according to the
manufacturer’s instructions.
Cell-cycle analysis was performed as described elsewhere (Haass
et al., 2008). In brief, on specific time points, cells were collected,
resuspended in PBS (Invitrogen), and ice-cold 70% ethanol (Sigma-
Aldrich) was added dropwise while mildly vortexing. After removing
ethanol, cells were washed with 0.05% Tween-20 (Sigma-Aldrich) in
PBS and then resuspended in DNA staining buffer (PBS/PI 10 mg ml/
RNase A 250 mg ml (Sigma-Aldrich). After 15 minutes incubation
at 371C, PI signal was acquired in FL-2 or FL-3 channel of a flow
cytometer using a linear scale (FACScan, BD Biosciences). Hypo-
diploid (necrotic/apoptotic), diploid (G1/G0), and tetraploid (G2/M)
cells were quantified using CellQuest software (BD Biosciences).
For confocal laser scanning microscopy (Axiovert 200M; Carl Zeiss
MicroImaging GmbH, Jena, Germany) analysis of cell nucleus after
Plk-1 siRNA treatment, the Propidium Iodide Nucleic Acid Stain (cat.
no. P-3566) protocol from Molecular Probes (Carlsbad, CA) was used.
Standard MTT assay was performed in 96-well plates
as described previously (Dabrowska-Iwanicka et al., 2002). The
viability was measured using following formula:
Relative viability ¼½ðexperimental absorbance  background absorbanceÞ=
ðabsorbance of untreated controls  background absorbanceÞ100%
Annexin V and caspase inhibition assays
For annexin V-based apoptosis detection assay, human melanoma
cell lines were collected at desired time points after Plk-1 siRNA
transfection or drug treatment. After washing in PBS (Invitrogen) cells
were resuspended in 1 Binding buffer (BD Biosciences), and
annexin V-FITC (BD Biosciences) and PI were added according to
the manufacturer’s protocols (BD Biosciences). After 15 minutes
incubation at room temperature, cells were acquired by flow
cytometry. All early apoptotic cells (annexin V positive) and
necrotic/late apoptotic cells (annexin V positive, PI positive), as
well as living cells (double negative) were detected by FACScan and
subsequently analyzed by CellQuest software (BD Biosciences).
For caspase inhibition assay, specific caspase-8 inhibitor,
Z-IETD-FMK and pan-caspase inhibitor Apo-Block (both from BD
Biosciences) were added to cell cultures 1 hour before Plk-1
silencing. DMSO-treated cells served as negative controls. Annexin
V staining was performed at desired time points.
WB analysis
For WB analysis, human melanoma cells were washed with cold
PBS (Invitrogen), lysed by treatment with radio immunoprecipitation
assay buffer (50 mM Tris base (Merck Chemicals, Darmstadt,
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Germany), 150 mM NaCl (Merck Chemicals), 1% NP-40 (Thermo
Fisher Scientific, Waltham, USA), 0.25% sodium deoxycholate
(Merck Chemicals), and 1 mM EDTA (Sigma-Aldrich)) in the presence
of a protease inhibitor cocktail (Complete, Mini Protease Inhibitor
Cocktail Tablets; Roche Diagnostics, Indianapolis, IN). Equal
amounts of proteins were separated on a 10, 12, or 15% (depending
on the molecular weight of proteins being detected) SDS poly-
acrylamide gel, transferred onto polyvinylidene difluoride mem-
branes (Sigma-Aldrich), and blocked with PBST (PBS/0.05% Tween-
20; Sigma-Aldrich) containing 5% non-fat dry milk (blocking buffer,
Bio-Rad, Hercules, CA). The membranes were incubated with
monoclonal mouse anti-human Plk-1 (ab 17057, Abcam plc),
polyclonal rabbit anti-human phospho-p44/42 MAPK (extracellular
signal-regulated kinase 1/2) (Thr202/Tyr204) (no. 9101, Cell Signaling
Technology, Danvers, MA), polyclonal rabbit anti-human-cleaved
caspase-3 (Asp175, no. 9661, Cell Signaling Technology), monoclonal
mouse anti-human-cleaved caspase-8 (1C12, no. 9746, Cell Signaling
Technology), monoclonal mouse anti-human p21 (ab54562, Abcam plc),
monoclonal mouse anti-human p53 (DO1, sc-126, Santa Cruz Biotech-
nology), polyclonal rabbit anti-human BID (no. 2002, Cell Signaling
Technology), monoclonal mouse anti-human Bcl-2 (100, sc-509, Santa
Cruz Biotechnology), monoclonal mouse anti-human cytochrome c (A-8,
no. sc-13156, Santa Cruz Biotechnology), or monoclonal mouse anti-
human a-tubulin (DM1A, no. CP06, Merck KGaA) antibodies in blocking
buffer overnight at 4oC according to the manufacturer’s instructions. After
extensive washing with PBST, the membranes were incubated for
45minutes at room temperature with a horseradish peroxidase-con-
jugated goat anti-mouse or goat anti-rabbit Ab (Bio-Rad) diluted 1:40,000
in blocking buffer. The membranes were subsequently washed in PBST
and proteins were visualized using ECL Western Blotting Detection
Reagents (GE Healthcare Europe, Munich, Germany).
MAPK inhibition
To study the expression of Plk-1 protein and cell viability after MAPK
inhibition, human melanoma cell lines WM-115 and M14 were
treated with specific inhibitors of MEK 1/2, PD98059 (10 mM), JNK
inhibitor II (16 mM), p38 inhibitor, SB203580 (20mM), and multikinase
inhibitor sorafenib (10 mM). DMSO-treated cells served as negative
controls. Cells were collected after 48 hour and subjected either to
annexin V assay or to protein extraction for WB analysis.
The effect of MAPK inhibition on cell cycle was studied by
treating human melanoma cells with specific MEK 1/2 inhibitor
PD98059 (10 mM) for 48 hours, followed by cell-cycle analysis as
explained above.
Statistics
Statistical analysis was performed using GraphPad-Instat software
(GraphPad, La Jolla, CA; http://www.graphpad.com). Multiple
groups (Plk-1 expression in tissues) were compared by one-way
analysis of variance with Tukey’s correction. Paired samples were
compared by paired t-test.
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